342 related articles for article (PubMed ID: 15970361)
1. Passive protection in the infant rat protection assay by sera taken before and after vaccination of teenagers with serogroup B meningococcal outer membrane vesicle vaccines.
Toropainen M; Saarinen L; Wedege E; Bolstad K; Mäkelä PH; Käyhty H
Vaccine; 2005 Sep; 23(40):4821-33. PubMed ID: 15970361
[TBL] [Abstract][Full Text] [Related]
2. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.
Wong S; Lennon D; Jackson C; Stewart J; Reid S; Crengle S; Tilman S; Aaberge I; O'Hallahan J; Oster P; Mulholland K; Martin D
Pediatr Infect Dis J; 2007 Apr; 26(4):345-50. PubMed ID: 17414400
[TBL] [Abstract][Full Text] [Related]
3. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.
Norheim G; Aase A; Caugant DA; Høiby EA; Fritzsønn E; Tangen T; Kristiansen P; Heggelund U; Rosenqvist E
Vaccine; 2005 May; 23(29):3762-74. PubMed ID: 15893613
[TBL] [Abstract][Full Text] [Related]
4. Meningococcal surrogates of protection--serum bactericidal antibody activity.
Borrow R; Balmer P; Miller E
Vaccine; 2005 Mar; 23(17-18):2222-7. PubMed ID: 15755600
[TBL] [Abstract][Full Text] [Related]
5. Human antibody responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine: results from ELISA studies.
Rosenqvist E; Høiby EA; Bjune G; Bryn K; Closs O; Feiring B; Klem A; Nøkleby H; Frølm LO
NIPH Ann; 1991 Dec; 14(2):169-79; discussion 180-1. PubMed ID: 1687481
[TBL] [Abstract][Full Text] [Related]
6. Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac.
Findlow J; Taylor S; Aase A; Horton R; Heyderman R; Southern J; Andrews N; Barchha R; Harrison E; Lowe A; Boxer E; Heaton C; Balmer P; Kaczmarski E; Oster P; Gorringe A; Borrow R; Miller E
Infect Immun; 2006 Aug; 74(8):4557-65. PubMed ID: 16861642
[TBL] [Abstract][Full Text] [Related]
7. Response of steroid-treated former preterm infants to a single dose of meningococcal C conjugate vaccine.
Clarke P; Robinson MJ; Ahmad I; Bedford-Russell AR; Connell JE; Powell PJ; Heath PT
Vaccine; 2006 Apr; 24(16):3273-8. PubMed ID: 16472548
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice.
Fukasawa LO; Dias WO; Schenkman RP; Raw I; Tanizaki MM
FEMS Immunol Med Microbiol; 2004 Jul; 41(3):205-10. PubMed ID: 15196569
[TBL] [Abstract][Full Text] [Related]
9. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
[TBL] [Abstract][Full Text] [Related]
10. Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.
Vermont CL; van Dijken HH; van Limpt CJ; de Groot R; van Alphen L; van Den Dobbelsteen GP
Infect Immun; 2002 Feb; 70(2):584-90. PubMed ID: 11796586
[TBL] [Abstract][Full Text] [Related]
11. Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis.
Toropainen M; Saarinen L; Wedege E; Bolstad K; Michaelsen TE; Aase A; Käyhty H
Infect Immun; 2005 Aug; 73(8):4694-703. PubMed ID: 16040982
[TBL] [Abstract][Full Text] [Related]
12. Phase II meningococcal B vesicle vaccine trial in New Zealand infants.
Jackson C; Lennon DR; Sotutu VT; Yan J; Stewart JM; Reid S; Crengle S; Oster P; Ypma E; Aaberge I; Mulholland K; Martin DR
Arch Dis Child; 2009 Oct; 94(10):745-51. PubMed ID: 18838420
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control.
Thornton V; Lennon D; Rasanathan K; O'Hallahan J; Oster P; Stewart J; Tilman S; Aaberge I; Feiring B; Nokleby H; Rosenqvist E; White K; Reid S; Mulholland K; Wakefield MJ; Martin D
Vaccine; 2006 Feb; 24(9):1395-400. PubMed ID: 16242221
[TBL] [Abstract][Full Text] [Related]
14. Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England.
Trotter C; Findlow J; Balmer P; Holland A; Barchha R; Hamer N; Andrews N; Miller E; Borrow R
Clin Vaccine Immunol; 2007 Jul; 14(7):863-8. PubMed ID: 17494636
[TBL] [Abstract][Full Text] [Related]
15. Serum opsonins to serogroup B meningococci after disease and vaccination.
Halstensen A; Lehmann AK; Guttormsen HK; Vollset SE; Bjune G; Naess A
NIPH Ann; 1991 Dec; 14(2):157-65; discussion 166-7. PubMed ID: 1812430
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers.
Bruge J; Bouveret-Le Cam N; Danve B; Rougon G; Schulz D
Vaccine; 2004 Mar; 22(9-10):1087-96. PubMed ID: 15003635
[TBL] [Abstract][Full Text] [Related]
17. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants.
Morley SL; Cole MJ; Ison CA; Camaraza MA; Sotolongo F; Anwar N; Cuevas I; Carbonero M; Campa HC; Sierra G; Levin M
Pediatr Infect Dis J; 2001 Nov; 20(11):1054-61. PubMed ID: 11734711
[TBL] [Abstract][Full Text] [Related]
19. Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock.
Jessouroun E; da Silveira IF; Larangeira AP; Pereira S; Fernandes SA; Rabinovitch L; Frasch CE; Castro-Faria-Neto HC; Bozza PT
Vaccine; 2004 Jun; 22(20):2617-25. PubMed ID: 15193387
[TBL] [Abstract][Full Text] [Related]
20. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease.
Frasch CE; Borrow R; Donnelly J
Vaccine; 2009 Jun; 27 Suppl 2():B112-6. PubMed ID: 19464093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
